Browse the evidence

Different fat depots exert different effects on the metabolic profile of individuals.

Practitioners should consider fat depot characteristics in metabolic assessments.

The mean total costs over 2 years were lower for MBS ($51,794) compared to GLP-1 receptor agonists ($63,483).

MBS may offer a more cost-effective long-term solution for obesity treatment.

The intervention group was more likely to achieve gestational weight gain (GWG) within recommendations compared to the control group (OR = 1.51; 95% CI (0.81, 2.80)).

Practitioners may consider structured nutrition and exercise interventions to help pregnant women achieve recommended weight gain.

Long-acting amylin analogues have beneficial effects on body weight in obesity.

Long-acting amylin analogues may be considered as a treatment option for obesity.

Cagrilintide, a novel amylin analogue, shows promising body weight reducing effects.

Cagrilintide may be an effective treatment for weight loss, especially when combined with other therapies.

The majority of studies reported %FFML exceeding 25%.

Most patients on GLP-1RAs may experience a significant proportion of weight loss from fat-free mass.

A growing number of new agents acting on incretin hormones are becoming available for clinical practice.

Clinicians should stay informed about new pharmacological options for treating obesity and T2DM.

For trials with mean baseline BMI <25, LDL cholesterol increased by 41 mg/dL on a low-carbohydrate diet.

Practitioners should be aware that low-carbohydrate diets may significantly raise LDL cholesterol in individuals with low BMI.

Preoperative discontinuation of semaglutide for > 21 days results in RGC similar to non-semaglutide users.

Practitioners should advise patients to discontinue semaglutide well in advance of procedures to reduce RGC risk.

The presence of ongoing digestive symptoms is significantly associated with increased RGC in semaglutide users.

Clinicians should monitor digestive symptoms in patients using semaglutide to assess RGC risk.

GLP-1 RA use was associated with lower medication use (RR, 0.53; 95% CI, 0.46-0.61; P < .001).

GLP-1 RAs may reduce the need for other medications in IIH management.

GLP-1 RA use was associated with reduced headaches (RR, 0.45; 95% CI, 0.35-0.58; P < .001).

GLP-1 RAs may help alleviate headache symptoms in IIH patients.

GLP-1 RA therapy is associated with significant reductions in procedural interventions (RR, 0.44; 95% CI, 0.30-0.63; P < .001).

GLP-1 RAs may reduce the need for surgical or other procedural interventions in IIH management.

Tirzepatide treatment results in an unprecedented improvement of glycaemic control and lowering of body weight.

Tirzepatide may be an effective treatment option for improving blood sugar levels and reducing weight in patients with type 2 diabetes.

High total carbohydrate intake is associated with high CVD morbidity (RR 1.08, 95% CI 1.02-1.13).

Limiting carbohydrate intake may help reduce the risk of cardiovascular disease.

High total fat intake is associated with a decreased all-cause mortality risk (RR 0.92, 95% CI 0.85-0.99).

Incorporating healthy fats into the diet may lower the risk of all-cause mortality.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduced the risk of any cardiovascular event in overweight or obese adults without diabetes.

GLP-1 RA can be considered for reducing cardiovascular risk in overweight or obese patients without diabetes.

In the study, 8.7% of participants receiving GLP-1 RA had a cardiovascular event compared to 11.2% of those receiving placebo.

The data indicates a lower incidence of cardiovascular events with GLP-1 RA treatment.

Bariatric surgery is currently the most effective long-term treatment for morbid obesity and type-2 diabetes mellitus.

Practitioners should consider bariatric surgery as a primary treatment option for patients with morbid obesity and type-2 diabetes.

GLP-1 RA treatment was associated with a significantly lower risk of all-cause mortality (hazard ratio 0.23; 95% confidence interval 0.15-0.34).

GLP-1 RAs may significantly reduce the risk of death in obese individuals without T2D.

GLP-1 RAs were associated with a lower risk of several cardiovascular complications, including ischaemic heart disease, heart failure, arrhythmias, hypertension, stroke, and atrial fibrillation.

GLP-1 RAs may help reduce the risk of serious cardiovascular issues in obese patients without T2D.

Injectable subcutaneous medications like semaglutide are gaining popularity for weight loss.

Practitioners should be aware of the increasing use of these medications for weight loss.

11% of adults aged 19-50 in the United States have habitual protein intakes below the Estimated Average Requirement (EAR) for a dietary Digestible Indispensable Amino Acid Score (DIAAS) of 100%.

Practitioners should assess protein intake adequacy in adults, particularly in the specified age group.

22% of adults aged 19-50 in the United States have habitual protein intakes below the Recommended Dietary Allowance (RDA).

Practitioners should ensure that adults meet the Recommended Dietary Allowance for protein.